Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IDO1 | P14902 | 7/20 | 0.63 |
| ▸ | PDE2A | O00408 | 2/20 | 0.35 |
| ▸ | USP30 | Q70CQ3 | 2/20 | 0.34 |
| ▸ | CA1 | P00915 | 1/20 | 0.34 |
| ▸ | CA2 | P00918 | 1/20 | 0.34 |
| ▸ | CA9 | Q16790 | 1/20 | 0.34 |
| ▸ | TDO2 | P48775 | 1/20 | 0.34 |
| ▸ | TACR1 | P25103 | 1/20 | 0.34 |
| ▸ | MRGPRX4 | Q96LA9 | 1/20 | 0.34 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.34 |
| ▸ | BACE1 | P56817 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3156002 | 0.86 | IDO1 (0.63) | IDO1PDE2ATACR1 | |
| SCHEMBL147418 | 0.80 | IDO1 (0.58) | IDO1PDE2AUSP30CA1CA2 | |
| SCHEMBL3153617 | 0.79 | TACR1 (0.46) | IDO1TACR1 | |
| SCHEMBL3162264 | 0.78 | IDO1 (0.41) | IDO1CA9TACR1 | |
| SCHEMBL5041166 | 0.78 | IDO1 (0.56) | IDO1USP30MRGPRX4 | |
| SCHEMBL18602429 | 0.74 | IDO1 (0.59) | IDO1PDE2AUSP30CA1CA2 | |
| SCHEMBL20303666 | 0.72 | IDO1 (0.58) | IDO1PDE2ACA1CA2CA9 | |
| SCHEMBL14255640 | 0.72 | IDO1 (0.58) | IDO1PDE2AUSP30MRGPRX4BACE1 | |
| SCHEMBL1167122 | 0.72 | IDO1 (0.58) | IDO1PDE2AUSP30CA1CA2 | |
| SCHEMBL268985 | 0.72 | IDO1 (0.58) | IDO1PDE2AUSP30CA1CA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100081693-A1 | THIADIAZOLE COMPOUND AND USE THEREOF | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2010-04-01 | — | — | US | disclosed |
| CN-101516878-A | Thiadiazole compound and use thereof | SUMITOMO CHEMICAL CO (JP) | 2009-08-26 | — | — | CN | disclosed |
| EP-2061789-A2 | THIADIAZOLE COMPOUND AND USE THEREOF | Sumitomo Chemical Company, Limited (JP) | 2009-05-27 | — | — | EP | disclosed |
| WO-2008032858-A2 | THIADIAZOLE COMPOUND AND USE THEREOF | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2008-03-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100081693-A1 | THIADIAZOLE COMPOUND AND USE THEREOF | NR2C2, NR4A3, NR0B2 | IDO1 1716/4885PDE2A 3220/4885USP30 2927/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.